Tivic Health Completes Optimization Study for Non-Invasive Vagus Nerve Stimulation Device.
ByAinvest
Wednesday, Jun 25, 2025 8:35 am ET1min read
AMPL--
The study, which concluded all study visits, focused on key parameters such as frequency, amplitude, electrode positioning, and personalization. These parameters are crucial for non-invasive vagus nerve stimulation (VNS) treatments, which have previously relied on under-researched aspects. Initial findings from the study underscore the importance of personalization for treatment effectiveness.
Tivic Health's Chief Executive Officer, Jennifer Ernst, stated, "This study has provided key breakthroughs in our scientific understanding of how to most effectively deliver stimulation to the vagus nerve and thereby modulate the pathways implicated in many prevalent and debilitating diseases." The company expects to release the study results later this year, which will inform the upcoming Phase I Clinical Trial.
The global VNS market is projected to grow from $8.59 billion in 2021 to $21.3 billion in 2030, according to Polaris Market Research [1]. Additionally, IDTechEx forecasts peripheral nerve stimulation, the segment targeted by Tivic Health, will grow at a 35% CAGR, one of the fastest growth segments in bioelectronic medicine [2].
Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients' immune systems. The company's lead biopharma product candidate, the TLR5 agonist Entolimod™ to treat ARS, has been granted Fast Track and Orphan Drug designation by the FDA. Tivic Health's bioelectronic program is developing non-invasive medical devices that personalize key stimulation to modulate the pathways implicated in many prevalent and debilitating diseases.
References:
[1] https://finance.yahoo.com/news/tivic-health-completes-optimization-study-123000936.html
[2] https://www.marketscreener.com/quote/stock/TIVIC-HEALTH-SYSTEMS-INC-129226105/news/Tivic-Health-Completes-Optimization-Study-for-Its-Non-Invasive-Vagus-Nerve-Stimulation-Device-50332249/
FTRK--
PII--
TIVC--
Tivic Health has completed an Optimization Study for its non-invasive cervical vagus nerve stimulation (ncVNS) device. The study, conducted by The Feinstein Institute of Bioelectronic Medicine, aims to identify optimal device parameters for therapeutic efficacy. Initial findings indicate the importance of personalization for treatment effectiveness. The study results will be released later this year and will inform the upcoming Phase I Clinical Trial.
FREMONT, Calif., June 19, 2025 — Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, has completed the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. The study, conducted by The Feinstein Institute of Bioelectronic Medicine, aims to identify optimal device parameters for therapeutic efficacy.The study, which concluded all study visits, focused on key parameters such as frequency, amplitude, electrode positioning, and personalization. These parameters are crucial for non-invasive vagus nerve stimulation (VNS) treatments, which have previously relied on under-researched aspects. Initial findings from the study underscore the importance of personalization for treatment effectiveness.
Tivic Health's Chief Executive Officer, Jennifer Ernst, stated, "This study has provided key breakthroughs in our scientific understanding of how to most effectively deliver stimulation to the vagus nerve and thereby modulate the pathways implicated in many prevalent and debilitating diseases." The company expects to release the study results later this year, which will inform the upcoming Phase I Clinical Trial.
The global VNS market is projected to grow from $8.59 billion in 2021 to $21.3 billion in 2030, according to Polaris Market Research [1]. Additionally, IDTechEx forecasts peripheral nerve stimulation, the segment targeted by Tivic Health, will grow at a 35% CAGR, one of the fastest growth segments in bioelectronic medicine [2].
Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients' immune systems. The company's lead biopharma product candidate, the TLR5 agonist Entolimod™ to treat ARS, has been granted Fast Track and Orphan Drug designation by the FDA. Tivic Health's bioelectronic program is developing non-invasive medical devices that personalize key stimulation to modulate the pathways implicated in many prevalent and debilitating diseases.
References:
[1] https://finance.yahoo.com/news/tivic-health-completes-optimization-study-123000936.html
[2] https://www.marketscreener.com/quote/stock/TIVIC-HEALTH-SYSTEMS-INC-129226105/news/Tivic-Health-Completes-Optimization-Study-for-Its-Non-Invasive-Vagus-Nerve-Stimulation-Device-50332249/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet